IL17A and psoriasis: The primary mechanism by which IL-17 antibodies attach to cytokines and prevent them from interacting with receptors to block the inflammatory cascade (10). A real-world study monitored 645 psoriasis patients taking ixekizumab and 1152 taking secukinumab for more than a year and showed lower discontinuation rates and higher adherence to ixekizumab (11).